VRDNViridian Therapeutics, Inc.

Viridian Therapeutics (VRDN) is set to see "minimal" revenue growth in H2 before inflecting meaningf

Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the 10 affordable biotech stocks to buy right now. On June 30, Goldman Sachs increased its target price for Viridian Therapeutics Inc. (NASDAQ:VRDN) from $35 to $39, implying an adjusted upside potential in excess of 105% at the prevailing level. The firm maintained its Buy rating on the […]

Viridian Therapeutics (VRDN) has drawn fresh investor attention after recent trading left the stock at $19.08. Recent performance has been mixed across different periods, and the company’s business remains focused on therapies for serious and rare diseases. See our latest analysis for Viridian Therapeutics. At a share price of $19.08, Viridian Therapeutics reflects a mixed picture, with a 30 day share price return of 16.70% and a 90 day share price return of 28.23%, alongside a year to date...

Viridian Therapeutics stock has fallen 37.8% year to date, yet the valuation checks still point to the shares looking expensive rather than like a clear bargain. The year to date decline of 37.8% raises the question of whether the recent weakness has gone far enough to justify the current share price. Future revenue potential from Viridian Therapeutics' pipeline can support higher expectations, but the need to fund ongoing development and potential cash burn may weigh on what investors are...

What to make of the markets today? The biggest story in recent months has been the conflict in the Middle East and its effect on oil prices. After pulling back for a while, crude has started moving higher again as geopolitical tensions raise concerns about potential supply disruptions. Meanwhile, the Federal Reserve left interest rates unchanged at its latest meeting. Although inflation has continued to cool overall, the recent move in oil reminds investors that geopolitical developments can sti